The largest drug companies are far more interested in enriching themselves and investors than in developing new drugs, according to a House committee report released Thursday
Read more...More frequent and severe New York City subway floods demonstrate how climate change is crippling critical infrastructure.
Read more...Trump is back for another misguided, erm, quixotic fight. Could he still score points?
Read more...Yves here. We’re doing a bit of catchup by featuring some significant stories that were still crowded out a bit due to the competing news plus the Fourth of July tuneout. One is on the super dodgy approval of the big ticket, very dubious effectiveness Alzheimer’s drug Aducanumab. And “big ticket” is no understatement; the […]
Read more...How do the rich intend to carry on as general conditions deteriorate?
Read more...An informant publicly recanting critically important testimony against Julian Assange seems unlikely to change the trajectory of his trial.
Read more...Covid and other major political challenges show that devising policies isn’t the hard part: it’s getting the public to go along.
Read more...Amazon looks to be having a meltdown over new FTC chief Lina Khan. Good.
Read more...Fifty years ago today, the United States Supreme Court allowed the publication of the Pentagon Papers to proceed.
Read more...Bad ideology, kept alive by lobbying and PR, has fueled an unproductive corporte tax race to the bottom. Is the tide finally turning?
Read more...The definition of what extremism amounts to becomes more, erm, inclusive as our elites feel more threatened. What are the possible end games?
Read more...Musing on how America wound up where it is.
Read more...California energy tsuris are set to get worse.
Read more...Questions about Louisiana’s plans to reroute the mighty Mississppi to save its eroding coast rattle the agency spearheading them
Read more...The pandemic is largely to be over in the Global North, at least among the vaccinated…or so it seems.
Read more...